PLoS ONE · 2015 · 37 citations · 32 references
MedicinePathobiologyPathologyRenal PathologyRenal PathophysiologyRenal PharmacotherapyChronic Kidney DiseaseFibrosisRenal DiseaseRenal FibrosisRenal InflammationTubulointerstitial DiseasesFibrosis InhibitionKidney DiseasesProinflammatory MediatorsRenal Fibrosis MechanismsRenal Interstitial InflammationType I Collagen DepositionType Iii Collagen DepositionUnilateral Ureteral Obstruction Model
BACKGROUND: Inflammation has a crucial role in renal interstitial fibrosis, which is the common pathway of chronic kidney diseases. Mefunidone (MFD) is a new compound which could effectively inhibit the proliferation of renal fibroblasts in vitro. However, the overall effect of Mefunidone in renal fibrosis remains unknown. METHODS: Sprague-Dawley rats were randomly divided intro 6 groups: sham operation, unilateral ureteral obstruction (UUO), UUO/Mefunidone (25, 50, 100mg/kg/day) and UUO/PFD (500mg/kg/day). The rats were sacrificed respectively on days 3, 7, and 14 after the operation. Tubulointerstitial injury index, interstitial collagen deposition, expression of fibronectin (FN), α-smooth muscle actin (α-SMA), type I and III collagen and the number of CD3+ and CD68+ cells were determined. The expressions of proinflammatory cytokines, p-ERK, p-IκB, and p-STAT3 were measured in human renal proximal tubular epithelial cells of HK-2 or macrophages. RESULTS: Mefunidone treatment significantly attenuated tubulointerstitial injury, interstitial collagen deposition, expression of FN, α-SMA, type I and III collagen in the obstructive kidneys, which correlated with significantly reduced the number of T cells and macrophages in the obstructive kidneys. Mechanistically, Mefunidone significantly inhibited tumor necrosis factor-α (TNF-α-) or lipopolysaccharide (LPS)-induced production of proinflammatory cytokines. This effect is possibly due to the inhibition of phosphorylation of ERK, IκB, and STAT3. CONCLUSION: Mefunidone treatment attenuated tubulointerstitial fibrosis in a rat model of UUO, at least in part, through inhibition of inflammation.
32
Prevalence of chronic kidney disease in China: a cross-sectional survey
Luxia Zhang, Fang Wang, Li Wang et al. · The Lancet · 2012 · 2.1K citations
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pablo E. Pérgola, Philip Raskin, Robert D. Toto et al. · New England Journal of Medicine · 2011 · 876 citations · Full text
Medicine, Endocrinology, Nephrology +16
Predicting renal outcome in IgA nephropathy.
M. Gene Radford, James V. Donadío, Eric J. Bergstralh et al. · Journal of the American Society of Nephrology · 1997 · 443 citations
Medicine, Nephrology, Pathology +17